Improved nasal bioavailability of elcatonin by insoluble powder formulation

Ishikawa, Fumihiko; Katsura, Masaki; Tamai, Ikumi; Tsuji, Akira

doi:10.1016/s0378-5173(01)00736-0

Cited by 49 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is in good agreement with reports in the literature; nasal particulate dosage forms have been shown to give an improved bioavailability of the delivered drugs compared with solutions, mainly due to their ability to reside longer in the nasal cavity before being cleared by the mucociliary clearance system and an increased topical concentration of the active substance by attaching to the powder particle (34,35). Low bioavailability from the solution formulations may be explained with faster drainage of intranasally applied solution.…”

Section: Nasal Absorption Of Mtc In Sheep Modelsupporting

confidence: 91%

Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation

Taş¹,

Özkan²,

Savaşer³

et al. 2009

Drug Delivery

View full text Add to dashboard Cite

Section: Nasal Absorption Of Mtc In Sheep Modelsupporting

confidence: 91%

Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation

Taş¹,

Özkan²,

Savaşer³

et al. 2009

Drug Delivery

View full text Add to dashboard Cite

“…Ishikawa et al [100] reported that powder formulation of elcatonin utilizing CaCO3 improves the nasal bioavailability by increasing residence time in the nasal cavity and thus enhances the systemic bioavailability. Recently Bergstrom et al [95] studied the uptake of picolinic acid (PA) in the brain.…”

Section: Delivery Of Non-peptide Molecules To the Cnsmentioning

confidence: 99%

Intranasal Drug Delivery for Brain Targeting

Vyas¹,

Shahiwala²,

Marathe³

et al. 2005

CDD

221

View full text Add to dashboard Cite

Many drugs are not being effectively and efficiently delivered using conventional drug delivery approach to brain or central nervous system (CNS) due to its complexity. The brain and the central nervous system both have limited accessibility to blood compartment due to a number of barriers. Many advanced and effective approaches to brain delivery of drugs have emerged in recent years. Intranasal drug delivery is one of the focused delivery options for brain targeting, as the brain and nose compartments are connected to each other via the olfactory route and via peripheral circulation. Realization of nose to brain transport and the therapeutic viability of this route can be traced from the ancient times and has been investigated for rapid and effective transport in the last two decades. Various models have been designed and studied by scientists to establish the qualitative and quantitative transport through nasal mucosa to brain. The development of nasal drug products for brain targeting is still faced with enormous challenges. A better understanding in terms of properties of the drug candidate, nose to brain transport mechanism, and transport to and within the brain is of utmost importance. This review will discuss some pertinent issues to be considered and challenges to brain targeted intranasal drug delivery. A few marketed and investigational drug formulations will also be discussed.

show abstract

“…The nasal powder formulations enhance systemic bioavailability, and are superior to liquid formulations [47,48] from the aspects of increased chemical stability of the drug, no requirement for preservatives in the formulations, and the feasibility of administering relatively large amounts of drug [49][50][51].…”

Section: Resultsmentioning

confidence: 99%

Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles

et al. 2011

View full text Add to dashboard Cite

Co-grinding is a procedure for the preparation of nanoparticles in which the drug is ground together with one or more excipients. The grinding of meloxicam, a crystalline solid, together with amorphous polyvinylpyrrolidone (PVP) or semi-crystalline polyethylene glycol (PEG) as excipients, is expected to lead to a drastic reduction in particle size. We optimized meloxicam grinding using a three level full factorial response surface design. In the case of PVP the optimum co-grinding parameter set in our study proved to be a meloxicam to PVP-C30 ratio of 1:1, and a rotation frequency of 400 rpm. The best size reduction was achieved at a meloxicam to PEG 6000 ratio = 1:2 at a rotation frequency of 400 rpm: nanoparticles averaging d SEM = 174 nm in diameter and with a very narrow size distribution (standard deviation 35% of mean) were obtained. X-ray powder diffraction analysis indicated that the optimized products contained amorphous meloxicam nanoparticles in the PVP-C30 composition, although meloxicam nanocrystals could also be detected in the samples which contained PEG 6000. The dissolution properties were significantly increased under nasal conditions (pH 5.1, temperature 30°C), especially in the case of the amorphous product. Such dry powder systems can offer novel opportunities in systemic nasal drug delivery.

show abstract

Improved nasal bioavailability of elcatonin by insoluble powder formulation

Cited by 49 publications

References 29 publications

Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation

Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation

Intranasal Drug Delivery for Brain Targeting

Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles

Contact Info

Product

Resources

About